文献速递生殖医学

低糖基化hFSH较完全糖基化hFSH更高效驱动卵泡发育

Hypo-glycosylated hFSH drives ovarian follicular development more efficiently than fully-glycosylated hFSH: enhanced transcription and PI3K and MAPK signaling.
PubMed 文献 · Hum Reprod · 2021-01-01

该研究在小鼠模型中比较了低糖基化(hFSH18/21)与完全糖基化(hFSH24)重组人FSH的体内生物活性。结果表明hFSH18/21促进更多大窦卵泡发育、卵泡健康指标更优,并更强激活转录活性及PI3K/AKT和MAPK/ERK信号通路,且未引起雌二醇过度升高。

要点

  • 低糖基化hFSH较完全糖基化hFSH促进更多大窦卵泡发育(P<0.01)。
  • hFSH18/21组卵泡健康指标更优,BAX/BCL2比值和cleaved Caspase 3更低。
  • hFSH18/21更强激活RTKs、PI3K/AKT和MAPK/ERK信号,抑制PI3K和MAPK可阻断促生长效应。

核心结论

  • 低糖基化hFSH较完全糖基化hFSH具有更高体内生物活性,能更有效促进卵泡健康和生长。
  • hFSH18/21通过增强转录活性及RTKs、PI3K/AKT和MAPK/ERK信号通路发挥作用。

研究设计与样本

  • 横断面研究,使用出生后第17天雌性CD-1小鼠。
  • 体内刺激组每组n=8-10只,腹腔注射PBS(150µl)、hFSH18/21(1µg/150µl PBS)或hFSH24(1µg/150µl PBS),每日两次(8:00和18:00),连续2天。
  • 急性处理组每组n=3-4只,体内处理2小时,一侧卵巢用于RNA测序,另一侧用于信号转导分析。
  • 采用体外卵巢培养系统验证信号通路。

主要发现

  • hFSH18/21较hFSH24促进显著更多大窦卵泡发育(P<0.01)。
  • hFSH18/21组BAX/BCL2比值和cleaved Caspase 3更低,卵泡健康指标更优。
  • 急性体内处理后,两种FSH糖基化形式均快速诱导卵巢转录,但hFSH18/21更强刺激Gαs和cAMP介导的信号及AP-1转录因子复合体成员。
  • hFSH18/21诱导RTKs、PI3K/AKT和MAPK/ERK信号激活显著强于hFSH24。
  • 抑制PI3K和MAPK可阻断FSH诱导的体外卵泡生长指标。

临床怎么用

  • 商业制备用于人类ART卵巢刺激的重组人FSH为完全糖基化FSH。
  • 低糖基化hFSH具有更高生物活性,促进卵泡健康和生长且未引起雌二醇过度产生,提示其用于人类ART的潜力。

局限性

  • 研究采用小鼠卵泡发育模型,hFSH糖基化形式生物活性差异需在非人灵长类中验证。
  • 基因表达研究反映的是全卵巢转录组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does hypo-glycosylated human recombinant FSH (hFSH18/21) have greater in vivo bioactivity that drives follicle development in vivo compared to fully-glycosylated human recombinant FSH (hFSH24)? SUMMARY ANSWER: Compared with fully-glycosylated hFSH, hypo-glycosylated hFSH has greater bioactivity, enabling greater follicular health and growth in vivo, with enhanced transcriptional activity, greater activation of receptor tyrosine kinases (RTKs) and elevated phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) and Mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signaling. WHAT IS KNOWN ALREADY: Glycosylation of FSH is necessary for FSH to effectively activate the FSH receptor (FSHR) and promote preantral follicular growth and formation of antral follicles. In vitro studies demonstrate that compared to fully-glycosylated recombinant human FSH, hypo-glycosylated FSH has greater activity in receptor binding studies, and more effectively stimulates the PKA pathway and steroidogenesis in human granulosa cells. STUDY DESIGN, SIZE, DURATION: This is a cross-sectional study evaluating the actions of purified recombinant human FSH glycoforms on parameters of follicular development, gene expression and cell signaling in immature postnatal day (PND) 17 female CD-1 mice. To stimulate follicle development in vivo, PND 17 female CD-1 mice (n = 8-10/group) were treated with PBS (150 µl), hFSH18/21 (1 µg/150 µl PBS) or hFSH24 (1 µg/150 µl PBS) by intraperitoneal injection (i.p.) twice daily (8:00 a.m. and 6:00 p.m.) for 2 days. Follicle numbers, serum anti-Müllerian hormone (AMH) and estradiol levels, and follicle health were quantified. PND 17 female CD-1 mice were also treated acutely (2 h) in vivo with PBS, hFSH18/21 (1 µg) or hFSH24 (1 µg) (n = 3-4/group). One ovary from each mouse was processed for RNA sequencing analysis and the other ovary processed for signal transduction analysis. An in vitro ovary culture system was used to confirm the relative signaling pathways. PARTICIPANTS/MATERIALS, SETTING, METHODS: The purity of different recombinant hFSH glycoforms was analyzed using an automated western blot system. Follicle numbers were determined by counting serial sections of the mouse ovary. Real-time quantitative RT-PCR, western blot and immunofluorescence staining were used to determine growth and apoptosis markers related with follicle health. RNA sequencing and bioinformatics were used to identify pathways and processes associated with gene expression profiles induced by acute FSH glycoform treatment. Analysis of RTKs was used to determine potential FSH downstream signaling pathways in vivo. Western blot and in vitro ovarian culture system were used to validate the relative signaling pathways. MAIN RESULTS AND THE ROLE OF CHANCE: Our present study shows that both hypo- and fully-glycosylated recombinant human FSH can drive follicular growth in vivo. However, hFSH18/21 promoted development of significantly more large antral follicles compared to hFSH24 (P < 0.01). In addition, compared with hFSH24, hFSH18/21 also promoted greater indices of follicular health, as defined by lower BAX/BCL2 ratios and reduced cleaved Caspase 3. Following acute in vivo treatment with FSH glycoforms RNA-sequencing data revealed that both FSH glycoforms rapidly induced ovarian transcription in vivo, but hypo-glycosylated FSH more robustly stimulated Gαs and cAMP-mediated signaling and members of the AP-1 transcription factor complex. Moreover, hFSH18/21 treatment induced significantly greater activation of RTKs, PI3K/AKT and MAPK/ERK signaling compared to hFSH24. FSH-induced indices of follicle growth in vitro were blocked by inhibition of PI3K and MAPK. LARGE SCALE DATA: RNA sequencing of mouse ovaries. Data will be shared upon reasonable request to the corresponding author. LIMITATIONS, REASONS FOR CAUTION: The observations that hFSH glycoforms have different bioactivities in the present study employing a mouse model of follicle development should be verified in nonhuman primates. The gene expression studies reflect transcriptomes of whole ovaries. WIDER IMPLICATIONS OF THE FINDINGS: Commercially prepared recombinant human FSH used for ovarian stimulation in human ART is fully-glycosylated FSH. Our findings that hypo-glycosylated hFSH has greater bioactivity enabling greater follicular health and growth without exaggerated estradiol production in vivo, demonstrate the potential for its development for application in human ART. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by NIH 1P01 AG029531, NIH 1R01 HD 092263, VA I01 BX004272, and the Olson Center for Women's Health. JSD is the recipient of a VA Senior Research Career Scientist Award (1IK6 BX005797). This work was also partially supported by National Natural Science Foundation of China (No. 31872352). The authors declared there are no conflicts of interest.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Hua G, George JW, Clark KL, et al. Hypo-glycosylated hFSH drives ovarian follicular development more efficiently than fully-glycosylated hFSH: enhanced transcription and PI3K and MAPK signaling. Hum Reprod. 2021. PMID: 34059912. doi:10.1093/humrep/deab135

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。